Regulating tumor suppressor genes: post-translational modifications.

Signal Transduction and Targeted Therapy
Ling ChenYongguang Tao

Abstract

Tumor suppressor genes cooperate with each other in tumors. Three important tumor suppressor proteins, retinoblastoma (Rb), p53, phosphatase, and tensin homolog deleted on chromosome ten (PTEN) are functionally associated and they regulated by post-translational modification (PTMs) as well. PTMs include phosphorylation, SUMOylation, acetylation, and other novel modifications becoming growing appreciated. Because most of PTMs are reversible, normal cells use them as a switch to control the state of cells being the resting or proliferating, and PTMs also involve in cell survival and cell cycle, which may lead to abnormal proliferation and tumorigenesis. Although a lot of studies focus on the importance of each kind of PTM, further discoveries shows that tumor suppressor genes (TSGs) form a complex "network" by the interaction of modification. Recently, there are several promising strategies for TSGs for they change more frequently than carcinogenic genes in cancers. We here review the necessity, characteristics, and mechanisms of each kind of post-translational modification on Rb, p53, PTEN, and its influence on the precise and selective function. We also discuss the current antitumoral therapies of Rb, p53 and PTEN as predictive...Continue Reading

References

Oct 1, 1976·Science·P C Nowell
Jan 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·G GoldsteinE A Boyse
Nov 27, 1992·Cell·T R HuppD P Lane
Jul 5, 1991·Science·M HollsteinC C Harris
Jan 1, 1990·Genes & Development·D P Lane, S Benchimol
Dec 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·D E Comings
Apr 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·A G Knudson
Jan 1, 1980·Cold Spring Harbor Symposia on Quantitative Biology·J M BishopH E Varmus
Jul 1, 1993·Genes & Development·X WuA J Levine
Jan 1, 1996·Life Sciences·F J Dumont, Q Su
Jan 1, 1996·World Journal of Urology·T W McGarvey, S B Malkowicz
Apr 24, 1997·Nature·K W Kinzler, B Vogelstein
May 15, 1997·Nature·Y HauptM Oren
Jun 19, 1997·Nature·N L LillD M Livingston
Jun 27, 1997·Cell·M L AvantaggiatiK Kelly
Jul 4, 1998·Oncogene·C W LeeN B La Thangue
Aug 8, 1998·Genes & Development·N Dyson
Sep 23, 1998·Genes & Development·K SakaguchiE Appella
Oct 6, 1998·Annual Review of Biochemistry·A Hershko, A Ciechanover
May 26, 1999·The Journal of Pathology·C Prives, P A Hall
Nov 24, 1999·The EMBO Journal·M S RodriguezR T Hay
Nov 24, 1999·The EMBO Journal·M GostissaG Del Sal
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·N H ChehabT D Halazonetis
Jan 5, 2000·Science·B A FosterF Rastinejad
Jan 25, 2000·Oncogene·P SandyG Del Sal
Feb 29, 2000·Cell·A Di Cristofano, P P Pandolfi
Apr 11, 2000·Molecular and Cellular Biology·M AshcroftK H Vousden
Jun 2, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G RazziniM Falasca
Jun 24, 2000·Molecular and Cellular Biology·F VazquezW R Sellers
Aug 10, 2000·The Journal of Biological Chemistry·Y HigashimotoC W Anderson
Oct 25, 2000·Molecular and Cellular Biology·M S RodriguezR T Hay

❮ Previous
Next ❯

Citations

Sep 16, 2020·Journal of Experimental & Clinical Cancer Research : CR·Shanshan ZhaoSong Zhang
Jan 31, 2021·Biomedicines·Vasiliki PapatheofaniStamatios Theocharis
Dec 10, 2020·Oxidative Medicine and Cellular Longevity·Xiang WeiDing-Sheng Jiang
Mar 5, 2021·Oncotarget·Andrew Henry LewisH Daniel Lacorazza
Mar 13, 2021·Frontiers in Oncology·Zhengfang LiuYidong Fan
May 26, 2021·Journal of Cardiovascular Translational Research·Ya-Fei LiLian-Sheng Wang
Jun 29, 2021·Frontiers in Oncology·María Paz SaldíasOscar Cerda
Jun 28, 2021·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Lingyue GaoLihui Wang
Aug 16, 2021·The Journal of Biological Chemistry·Nathan A Snyder, Gustavo M Silva
Aug 27, 2021·Amino Acids·Anna Di FioreGiuseppina De Simone
Sep 28, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Zong Sheng Guo, Zhaoxia Qu
Dec 23, 2021·Journal of Biomolecular Structure & Dynamics·Wan-Atirah AzeminMohd Shahir Shamsir

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
MDS
neddylation
acetylation
sumoylation
de-ubiquitination
xenograft
gene knockout
glycosylation

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.